Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

被引：2
|
作者：
Reza, Nosheen [1 ]
Dubey, Anandkumar [2 ]
Carattini, Thomas [2 ]
Marzolf, Amy [1 ]
Hornsby, Nicole [1 ]
de Feria, Alejandro [1 ]
Mahmud, Nadim [1 ]
Schuler, Patricia [2 ]
Owens, Anjali Tiku [1 ]
机构：
[1] Univ Penn, Perelman Sch Med, Philadelphia, PA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
来源：
JACC-HEART FAILURE | 2024年 / 12卷 / 06期
关键词：
D O I：
10.1016/j.jchf.2024.03.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1123 / 1125
页数：3
相关论文
共 50 条
  • [21] Real-world treatment patterns of mavacamten and associated background therapies in patients with obstructive hypertrophic cardiomyopathy (HCM) in the United States
    Masri, Ahmad
    Hernandez, Ervant Maksabedian
    Schuler, Patricia
    Wang, Yan
    Gao, Weihua
    Wu, Aozhou
    Han, Xu
    CIRCULATION, 2024, 150
  • [22] Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
    Zhang, Jing
    Ji, Chao
    Cheng, Bo
    Ruan, Shi-Fan
    Liu, Tao
    Huang, Jin-Wen
    CHINESE MEDICAL JOURNAL, 2020, 133 (24) : 3020 - 3022
  • [23] Sex Differences In Characteristics Of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Initiated On Mavacamten
    Duqueney, Estherland
    Reza, Nosheen
    Boakye, Ellen
    Marzolf, Amy
    Hornsby, Nicole
    DE Feria, Alejandro
    Owens, Anjali
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [24] Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
    Lima, M. R. L.
    Bello, A. R. B.
    Maltes, S. M.
    Laranjeira, T. L.
    Cunha, G. C.
    Adragao, P. A.
    Rocha, B. R.
    Aguiar, C. A.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [25] COST-EFFECTIVENESS OF MAVACAMTEN FOR THE TREATMENT OF PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN THE NETHERLANDS
    Buisman, L.
    Treur, M.
    Verkaik, M.
    Van De Wetering, G.
    Pronk, L. M.
    Pompen, M.
    Hurst, M.
    VALUE IN HEALTH, 2023, 26 (12) : S110 - S110
  • [26] Mavacamten in a real-world hypertrophic cardiomyopathy population: how many may be eligible?
    Lima, M. R. L.
    Bello, A. R. B.
    Maltes, S. M.
    Laranjeira, T. L.
    Cunha, G. L. C.
    Adragao, P. A.
    Rocha, B. R.
    Aguiar, C. A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 513 - 513
  • [27] Long-Term Efficacy and Safety of Mavacamten in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
    Day, Sharlene M.
    Udelson, James E.
    Bonow, Robert O.
    JAMA CARDIOLOGY, 2023, 8 (10) : 978 - 978
  • [28] Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
    Maurizi, Niccolo
    Chiriatti, Chiara
    Fumagalli, Carlo
    Targetti, Mattia
    Passantino, Silvia
    Antiochos, Panagiotis
    Skalidis, Ioannis
    Chiti, Chiara
    Biagioni, Giulia
    Tomberli, Alessia
    Giovani, Sara
    Coppini, Raffaele
    Cecchi, Franco
    Olivotto, Iacopo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (07)
  • [29] COST-EFFECTIVENESS OF MAVACAMTEN FOR THE TREATMENT OF PATIENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) IN FRANCE
    Cotte, F. E.
    Hurst, M.
    Akarkoub, S.
    Ho, M.
    Vernon, J.
    Chambry, L.
    Vega, V.
    Leproust, S.
    VALUE IN HEALTH, 2024, 27 (12) : S64 - S64
  • [30] Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM
    Masri, Ahmad
    Barriales-Villa, Roberto
    Elliott, Perry
    Nassif, Michael E.
    Oreziak, Artur
    Owens, Anjali T.
    Tower-Rader, Albree
    Heitner, Stephen B.
    Kupfer, Stuart
    Malik, Fady I.
    Melloni, Chiara
    Meng, Lisa
    Wei, Jenny
    Saberi, Sara
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (09) : 1993 - 1998
12345